[68Ga]Ga-DOTA-FAPI-04 PET/CT 在非小细胞肺癌临床分期中的准确性高于 2-[18F]FDG PET/CT
该前瞻性研究纳入 134 例确诊或疑似非小细胞肺癌(NSCLC)患者,行配对 2-[18F]FDG PET/CT 与 [68Ga]Ga-DOTA-FAPI-04 PET/CT,并对其中 74 例有病理结果者进行回顾性分期分析。结果显示 [68Ga]Ga-DOTA-FAPI-04 在 T、N、M 分期及总体分期准确性上均优于 2-[18F]FDG,尤其在局限期病变患者中。
要点
- T 诊断:79 个肺结节中 [68Ga]Ga-DOTA-FAPI-04 优于 2-[18F]FDG,尤其非实性和小尺寸腺癌结节
- N 分期:转移性淋巴结识别准确率 [68Ga]Ga-DOTA-FAPI-04 94% vs 2-[18F]FDG 30%(P < 0.001)
- 总体分期准确率 [68Ga]Ga-DOTA-FAPI-04 82.7%(43/52)vs 2-[18F]FDG 51.9%(27/52),P = 0.001
核心结论
- 与 2-[18F]FDG PET/CT 相比,[68Ga]Ga-DOTA-FAPI-04 PET/CT 在不同病理分期的 NSCLC 患者中表现出更好的分期性能,尤其是局限期病变患者。
研究设计与样本
- 前瞻性研究(ChiCTR2000038080)纳入 134 例确诊或疑似 NSCLC 患者,均接受配对 2-[18F]FDG PET/CT 与 [68Ga]Ga-DOTA-FAPI-04 PET/CT。
- 对其中 74 例有病理结果的 NSCLC 患者进行回顾性分析,比较原发肿瘤(T)、淋巴结(N)和转移灶(M)分期性能。
主要发现
- T 诊断:在 72 例患者的 79 个肺结节中,[68Ga]Ga-DOTA-FAPI-04 的诊断性能优于 2-[18F]FDG,尤其对非实性和小尺寸腺癌结节。
- N 分期:分析 37 例患者的 98 个有病理结果的淋巴结,[68Ga]Ga-DOTA-FAPI-04 在非转移性淋巴结中的 SUVmax 显著低于转移性淋巴结。
- M 分期:在 14 例多发转移患者中,[68Ga]Ga-DOTA-FAPI-04 识别出更多病灶(257 个 vs 139 个)。
- 总体分期:在 52 例不同病理分期的患者中,[68Ga]Ga-DOTA-FAPI-04 的总体分期准确率优于 2-[18F]FDG[43/52(82.7%)vs 27/52(51.9%),P = 0.001]。
关键数值与推荐
- 转移性淋巴结识别:[68Ga]Ga-DOTA-FAPI-04 SUVmax 最佳截断值为 5.5,使用 [68Ga]Ga-DOTA-FAPI-04 和 2-[18F]FDG 标准的诊断准确率分别为 94% 和 30%(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to explore the clinical staging performance of [68 Ga]Ga-DOTA-FAPI-04 PET/CT compared with that of 2-[18F]FDG PET/CT in non-small cell lung cancer (NSCLC) patients lesion by lesion. METHODS: A total of 134 diagnosed or suspected NSCLC patients were enrolled in the prospective study (ChiCTR2000038080); they received paired 2-[18F]FDG PET/CT and [68 Ga]Ga-DOTA-FAPI-04 PET/CT. Of these patients, the retrospective analysis of 74 NSCLC patients with pathological results was conducted from primary tumor (T) diagnosis, lymph node (N), and metastatic lesion (M) staging. The imaging characteristics of the lung nodules and suspected metastases were obtained and analyzed, and the staging performance of 2-[18F]FDG PET/CT and [68 Ga]Ga-DOTA-FAPI-04 PET/CT was compared. RESULTS: For T diagnosis, [68 Ga]Ga-DOTA-FAPI-04 showed better diagnostic performance than 2-[18F]FDG in 79 lung nodules of 72 patients, especially for nonsolid and small-dimension adenocarcinoma nodules. For N staging, 98 lymph nodes (LNs) with pathological results in 37 patients were analyzed. The SUVmax of [68 Ga]Ga-DOTA-FAPI-04 in the nonmetastatic LNs was significantly lower than that in the metastatic LNs. Regarding metastatic LN identification, the calculated optimum cut-off value of [68 Ga]Ga-DOTA-FAPI-04 SUVmax was 5.5, and the diagnostic accuracy using [68 Ga]Ga-DOTA-FAPI-04 and 2-[18F]FDG criteria was 94% and 30%, respectively (P < 0.001). For M staging, [68 Ga]Ga-DOTA-FAPI-04 identified more lesions than 2-[18F]FDG (257 vs. 139 lesions) in 14 patients with multiple metastases. Overall, the staging accuracy of [68 Ga]Ga-DOTA-FAPI-04 was better than that of 2-[18F]FDG in 52 patients with different pathological stages [43/52 (82.7%) vs. 27/52 (51.9%), P = 0.001]. CONCLUSION: Compared with 2-[18F]FDG PET/CT, [68 Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated better staging performance in NSCLC patients with different pathological stages, especially those with localized disease.
引用
- Zhou X, Wang S, Xu X, et al. Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC. Eur J Nucl Med Mol Imaging. 2022. PMID: 35543731. doi:10.1007/s00259-022-05818-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。